Author: matias iglicki (Argentina)
Co-authors: prof Paolo Lanzetta, Catharina Busch, Marco Lupidi, Jay Chahhblani, Dinah Zur, Prof Anat Loewestein
Purpose
We aimed to compare visual and anatomical outcome in vitrectomized and non- vitrectomized eyes treated with Dexamethasone (DEX) implant due to diabetic macular edema (DME). Design: Multicenter, retrospective, interventional study. Participants: 236 eyes from 234 patients with DME with or without previous vitrectomy performed with a follow up of 12 months.
Setting/Venue
Multicenter, retrospective, interventional study. Participants: 236 eyes from 234 patients with DME with or without previous vitrectomy performed with a follow up of at least 12 months involving multiple sites
Methods
Methods: Main outcome measures: Change from baseline best corrected visual acuity (BCVA) and central subfoveal thickness (CST) over follow-up period. Secondary outcomes: cataract rate formation, intraocular pressure increase, number of implants needed.
Results
The non-vitrectomized group included 130 eyes (55.1%), the vitrectomized group included 106 eyes (44.9%). The groups were well balanced for age and gender (p=0.540, and p=0.053, respectively). Both groups showed statistically significant improvement in BCVA and CST (for all groups: p<0.001). There was no significant difference between the groups in terms of change in vision (p=0.89) and anatomy (p=0.65). The mean number of DEX implants given during follow-up was 3.5 in both groups, and there was no significant difference between the groups (p=0.81).
Conlusions
In patients with DME, we demonstrated similar anatomical and functional efficacy of DEX implant in non-vitrectomized and vitrectomized eyes. Its efficacy was not decreased by the consequences of full vitrectomy for Diabetic retinopathy complications. Safety profile was very well balanced between the groups.
Financial Disclosure
Allergan – Consultant -Bayer - Consultant -Novartis- Consultant -Regeneron- PI -Genentech-PI -TSK Laboratory Europe B.V. consultan
Comments
-